Literature DB >> 17459355

Pivotal role of cardiac lineage protein-1 (CLP-1) in transcriptional elongation factor P-TEFb complex formation in cardiac hypertrophy.

Jorge Espinoza-Derout1, Michael Wagner, Katayoun Shahmiri, Eduardo Mascareno, Brahim Chaqour, M A Q Siddiqui.   

Abstract

OBJECTIVE: Our aim was to determine if the expression pattern of CLP-1 in developing heart is consistent with its role in controlling RNA transcript elongation by transcriptional elongation factor b (P-TEFb) and if the inhibitory control exerted over P-TEFb by CLP-1 is released under hypertrophic conditions.
METHODS: We performed immunoblot and immunofluorescence analysis of CLP-1 and the P-TEFb components cdk9 and cyclin T in fetal mouse heart and 2 day post-natal mouse cardiomyocytes to determine if they are co-localized. We induced hypertrophy in rat cardiomyocytes either by mechanical stretch or treatment with hypertrophic agents such as endothelin-1 and phenylephrine to determine if CLP-1 is released from P-TEFb in response to hypertrophic stimuli. The involvement of the Jak/STAT signal transduction pathway in this process was studied by blocking this pathway with the Jak2 kinase inhibitor, AG490, and assessing the association of CLP-1 with P-TEFb complexes.
RESULTS: We found that CLP-1 is expressed along with P-TEFb components in developing heart during the period in which knockout mice lacking the CLP-1 gene develop cardiac hypertrophy and die. Under conditions of hypertrophy induced by mechanical stretch or agonist treatment, CLP-1 dissociates from the P-TEFb complex, a finding consistent with the de-repression of P-TEFb kinase activity seen in hypertrophic cardiomyocytes. Blockage of Jak/STAT signaling by AG490 prevented release of CLP-1 from P-TEFb despite the ongoing presence of hypertrophic stimulation by mechanical stretch.
CONCLUSIONS: CLP-1 expression in developing heart and isolated post-natal cardiomyocytes colocalizes with P-TEFb expression and therefore has the potential to regulate RNA transcript elongation by controlling P-TEFb cdk9 kinase activity in heart. We further conclude that the dissociation of CLP-1 from P-TEFb is responsive to hypertrophic stimuli transduced by cellular signal transduction pathways. This process may be part of the genomic stress response resulting in increased RNA transcript synthesis in hypertrophic cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459355      PMCID: PMC2778048          DOI: 10.1016/j.cardiores.2007.03.019

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  48 in total

1.  Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart.

Authors:  J Pan; K Fukuda; H Kodama; S Makino; T Takahashi; M Sano; S Hori; S Ogawa
Journal:  Circ Res       Date:  1997-10       Impact factor: 17.367

Review 2.  Changes in gene expression during cardiac growth.

Authors:  A M Lompré; J J Mercadier; K Schwartz
Journal:  Int Rev Cytol       Date:  1991

3.  Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase.

Authors:  N F Marshall; J Peng; Z Xie; D H Price
Journal:  J Biol Chem       Date:  1996-10-25       Impact factor: 5.157

4.  Identification of multiple cyclin subunits of human P-TEFb.

Authors:  J Peng; Y Zhu; J T Milton; D H Price
Journal:  Genes Dev       Date:  1998-03-01       Impact factor: 11.361

5.  Signal transduction and activator of transcription (STAT) protein-dependent activation of angiotensinogen promoter: a cellular signal for hypertrophy in cardiac muscle.

Authors:  E Mascareno; M Dhar; M A Siddiqui
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

6.  Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes.

Authors:  H Kodama; K Fukuda; J Pan; S Makino; A Baba; S Hori; S Ogawa
Journal:  Circ Res       Date:  1997-11       Impact factor: 17.367

Review 7.  The cellular and molecular response of cardiac myocytes to mechanical stress.

Authors:  J Sadoshima; S Izumo
Journal:  Annu Rev Physiol       Date:  1997       Impact factor: 19.318

8.  Patterns of mRNA expression during early cell growth differ in kidney epithelial cells destined to undergo compensatory hypertrophy versus regenerative hyperplasia.

Authors:  J T Norman; R E Bohman; G Fischmann; J W Bowen; A McDonough; D Slamon; L G Fine
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

Review 9.  Modulation of contractility in human cardiac hypertrophy by myosin essential light chain isoforms.

Authors:  M C Schaub; M A Hefti; R A Zuellig; I Morano
Journal:  Cardiovasc Res       Date:  1998-02       Impact factor: 10.787

10.  Endothelin-1, phorbol esters and phenylephrine stimulate MAP kinase activities in ventricular cardiomyocytes.

Authors:  M A Bogoyevitch; P E Glennon; P H Sugden
Journal:  FEBS Lett       Date:  1993-02-15       Impact factor: 4.124

View more
  14 in total

1.  Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor β (TGF-β1) signaling axis.

Authors:  Eduardo Mascareno; Josephine Galatioto; Inna Rozenberg; Louis Salciccioli; Haroon Kamran; Jason M Lazar; Fang Liu; Thierry Pedrazzini; M A Q Siddiqui
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

Review 2.  RNA polymerase II transcription elongation control.

Authors:  Jiannan Guo; David H Price
Journal:  Chem Rev       Date:  2013-08-06       Impact factor: 60.622

Review 3.  Hexim1, an RNA-controlled protein hub.

Authors:  Annemieke A Michels; Olivier Bensaude
Journal:  Transcription       Date:  2018-02-23

4.  The positive transcription elongation factor b is an essential cofactor for the activation of transcription by myocyte enhancer factor 2.

Authors:  Masanori Nojima; Yehong Huang; Mudit Tyagi; Hung-Ying Kao; Koh Fujinaga
Journal:  J Mol Biol       Date:  2008-07-16       Impact factor: 5.469

5.  Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1.

Authors:  Jorge Espinoza-Derout; Michael Wagner; Louis Salciccioli; Jason M Lazar; Sikha Bhaduri; Eduardo Mascareno; Brahim Chaqour; M A Q Siddiqui
Journal:  Circ Res       Date:  2009-05-14       Impact factor: 17.367

6.  Caffeine prevents transcription inhibition and P-TEFb/7SK dissociation following UV-induced DNA damage.

Authors:  Giuliana Napolitano; Stefano Amente; Virginia Castiglia; Barbara Gargano; Vera Ruda; Xavier Darzacq; Olivier Bensaude; Barbara Majello; Luigi Lania
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

7.  BET acetyl-lysine binding proteins control pathological cardiac hypertrophy.

Authors:  Jessica I Spiltoir; Matthew S Stratton; Maria A Cavasin; Kim Demos-Davies; Brian G Reid; Jun Qi; James E Bradner; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2013-08-09       Impact factor: 5.000

Review 8.  BET-ting on chromatin-based therapeutics for heart failure.

Authors:  Saptarsi M Haldar; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2014-05-14       Impact factor: 5.000

9.  P-TEFb- the final frontier.

Authors:  Jiri Kohoutek
Journal:  Cell Div       Date:  2009-09-02       Impact factor: 5.130

Review 10.  CDK9 keeps RNA polymerase II on track.

Authors:  Sylvain Egloff
Journal:  Cell Mol Life Sci       Date:  2021-06-19       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.